Adult Still's disease: New horizons
Still's disease in children (systemic juvenile idiopathic arthritis - JIA) and adult Still's disease (ASD) are considered as systemic autoinflammatory diseases of unknown etiology, which are based on similar immunopathogenetic mechanisms associated with genetically determined disorders of...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2021-12-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/3096 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849687944240037888 |
|---|---|
| author | E. L. Nasonov E. Feist |
| author_facet | E. L. Nasonov E. Feist |
| author_sort | E. L. Nasonov |
| collection | DOAJ |
| description | Still's disease in children (systemic juvenile idiopathic arthritis - JIA) and adult Still's disease (ASD) are considered as systemic autoinflammatory diseases of unknown etiology, which are based on similar immunopathogenetic mechanisms associated with genetically determined disorders of the mechanisms of innate immunity. ASD was first described 50 years ago by the English rheumatologist Eric George Lapthorne Bywaters. The molecular basis of ASD immunopathogenesis is the activation of innate immunity associated with NLRP3 inflammasome-dependent mechanisms of inflammation, characterized by the overproduction of “pro-inflammatory” cytokines - interleukin (IL) 1 and IL-18, inducing the synthesis of other proinflammatory inflammatory mediators. A review of new data concerning the mechanisms of immunopathology, clinical polymorphism, laboratory biomarkers and the possibilities of ASD pharmacotherapy is presented.Particular attention is paid to the prospects for the use of monoclonal antibodies to IL-1β - canakinumab. The problems associated with the generality of clinical and laboratory disorders, pathogenetic mechanisms and pharmacotherapy of ASD and coronavirus disease 2019 (COVID-19) are considered. |
| format | Article |
| id | doaj-art-3cc5b08c5b264333b68e9cfebc84bcb4 |
| institution | DOAJ |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2021-12-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-3cc5b08c5b264333b68e9cfebc84bcb42025-08-20T03:22:12ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922021-12-0159664566510.47360/1995-4484-2021-643-6632760Adult Still's disease: New horizonsE. L. Nasonov0E. Feist1V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Department of Rheumatology, Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto-von-Guericke University MagdeburgStill's disease in children (systemic juvenile idiopathic arthritis - JIA) and adult Still's disease (ASD) are considered as systemic autoinflammatory diseases of unknown etiology, which are based on similar immunopathogenetic mechanisms associated with genetically determined disorders of the mechanisms of innate immunity. ASD was first described 50 years ago by the English rheumatologist Eric George Lapthorne Bywaters. The molecular basis of ASD immunopathogenesis is the activation of innate immunity associated with NLRP3 inflammasome-dependent mechanisms of inflammation, characterized by the overproduction of “pro-inflammatory” cytokines - interleukin (IL) 1 and IL-18, inducing the synthesis of other proinflammatory inflammatory mediators. A review of new data concerning the mechanisms of immunopathology, clinical polymorphism, laboratory biomarkers and the possibilities of ASD pharmacotherapy is presented.Particular attention is paid to the prospects for the use of monoclonal antibodies to IL-1β - canakinumab. The problems associated with the generality of clinical and laboratory disorders, pathogenetic mechanisms and pharmacotherapy of ASD and coronavirus disease 2019 (COVID-19) are considered.https://rsp.mediar-press.net/rsp/article/view/3096adult still's diseaseinterleukin 1covid-19canakinumabbiologics |
| spellingShingle | E. L. Nasonov E. Feist Adult Still's disease: New horizons Научно-практическая ревматология adult still's disease interleukin 1 covid-19 canakinumab biologics |
| title | Adult Still's disease: New horizons |
| title_full | Adult Still's disease: New horizons |
| title_fullStr | Adult Still's disease: New horizons |
| title_full_unstemmed | Adult Still's disease: New horizons |
| title_short | Adult Still's disease: New horizons |
| title_sort | adult still s disease new horizons |
| topic | adult still's disease interleukin 1 covid-19 canakinumab biologics |
| url | https://rsp.mediar-press.net/rsp/article/view/3096 |
| work_keys_str_mv | AT elnasonov adultstillsdiseasenewhorizons AT efeist adultstillsdiseasenewhorizons |